纳维诺医药科技

Navino Pharmaceutical is a biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative small molecule drugs. The company leverages its proprietary molecular glue and targeted protein degradation (TPD) platforms to address undruggable targets, particularly in the fields of oncology and immunology. Founded by experts in medicinal chemistry and structural biology, Navino aims to create next-generation therapies by modulating protein-protein interactions. Their pipeline currently consists of several pre-clinical programs focused on high-value targets with significant unmet medical needs. The company is backed by prominent venture capital firms including Oriza Seed and Kaitai Capital.